{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:36:58Z","timestamp":1793835418821,"version":"4.6.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005261","name":"Centre Hospitalier R\u00e9gional Universitaire de Montpellier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Forensic Science International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.forsciint.2025.112763","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T16:04:42Z","timestamp":1765209882000},"page":"112763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Postmortem distribution of isotonitazene and its three metabolites in the first lethal case observed in France"],"prefix":"10.1016","volume":"379","author":[{"given":"J.-J.","family":"Bendjilali-Sabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Eiden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lossois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Martrille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Peyriere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.forsciint.2025.112763_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/dta.2738","article-title":"Report on a novel emerging class of highly potent benzimidazole NPS opioids: chemical and in vitro functional characterization of isotonitazene","volume":"12","author":"Blanckaert","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.forsciint.2025.112763_bib2","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1007\/s00204-020-02855-7","article-title":"In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances","volume":"94","author":"Vandeputte","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/jat\/bkaa016","article-title":"Isotonitazene quantitation and metabolite discovery in authentic forensic casework","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00213-022-06292-5","article-title":"Plasma pharmacokinetics and pharmacodynamic effects of the 2-benzylbenzimidazole synthetic opioid, isotonitazene, in male rats","volume":"240","author":"Walton","year":"2023","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.forsciint.2025.112763_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2024.05.004","article-title":"Isotonitazene, a synthetic opioid from an emerging family: the nitazenes","author":"Bendjilali-Sabiani","year":"2024","journal-title":"Therapies"},{"key":"10.1016\/j.forsciint.2025.112763_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2021.110686","article-title":"Isotonitazene: fatal intoxication in three cases involving this unreported novel psychoactive substance in Switzerland","volume":"320","author":"Mueller","year":"2021","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.forsciint.2025.112763_bib7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jat\/bkab117","article-title":"A forward-thinking approach to addressing the new synthetic opioid 2-benzylbenzimidazole nitazene analogs by liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS)","volume":"46","author":"Walton","year":"2022","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib8","unstructured":"U.S. Food and Drug, Administration. FDA, U.S. Food and Drug Administration C for DE and Analytical Procedures and Methods Validation for Drugs and Biologics (Internet), 2020. \u3008https:\/\/www.fda.gov\/regulatory-information\/searchfda- guidance-documents\/analytical-procedures-and-methods-validation-drugsand- biologics\u3009. (Accessed 21 Juill 2022)."},{"key":"10.1016\/j.forsciint.2025.112763_bib9","unstructured":"European Medicines Agency, ICH M10 on Bioanalytical Method Validation, European Medicines Agency 2023. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf\u3009 (accessed November 24, 2025)."},{"key":"10.1016\/j.forsciint.2025.112763_bib10","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00204-024-03774-7","article-title":"In vitro structure\u2013activity relationships and forensic case series of emerging 2-benzylbenzimidazole \u2018nitazene\u2019 opioids","volume":"98","author":"De Vrieze","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib11","unstructured":"EMCDDA, Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation No 1920\/2006, European Union Drugs Agency (n.d.), 2020.https:\/\/doi.org\/10.2810\/370922."},{"key":"10.1016\/j.forsciint.2025.112763_bib12","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1021\/acschemneuro.1c00037","article-title":"DARK classics in chemical neuroscience: etonitazene and related benzimidazoles","volume":"12","author":"Ujv\u00e1ry","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.forsciint.2025.112763_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1434573","article-title":"Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes","volume":"15","author":"Jadhav","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.forsciint.2025.112763_bib14","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s00204-024-03735-0","article-title":"Human metabolism of four synthetic benzimidazole opioids: isotonitazene, metonitazene, etodesnitazene, and metodesnitazene","volume":"98","author":"Taoussi","year":"2024","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib15","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425255.2021.1908262","article-title":"Drug metabolism in the lungs: opportunities for optimising inhaled medicines","volume":"17","author":"Enlo-Scott","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.forsciint.2025.112763_bib17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1515\/cclm-2023-1360","article-title":"In vitro, in vivo metabolism and quantification of the novel synthetic opioid N-piperidinyl etonitazene (etonitazepipne)","volume":"62","author":"Berardinelli","year":"2024","journal-title":"Clin. Chem. Lab Med."},{"key":"10.1016\/j.forsciint.2025.112763_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/FTD.0000000000000970","article-title":"Acute intoxications and fatalities associated with benzimidazole opioid (nitazene analog) use: a systematic review","volume":"44","author":"Montanari","year":"2022","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.forsciint.2025.112763_bib19","first-page":"S70","article-title":"Clinical pharmacology, toxicity, and abuse potential of opioids","volume":"61","author":"Vearrier","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.forsciint.2025.112763_bib20","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bph.15580","article-title":"Understanding and countering opioid-induced respiratory depression","volume":"180","author":"Bateman","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.forsciint.2025.112763_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/15563650.2025.2504133","article-title":"Nitazenes: review of comparative pharmacology and antagonist action","volume":"63","author":"Stangeland","year":"2025","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.forsciint.2025.112763_bib22","article-title":"Wooden chest syndrome: a case report of fentanyl-induced chest wall rigidity","volume":"9","author":"Rosal","year":"2021","journal-title":"J. Investig.. Med High. Impact Case Rep."},{"key":"10.1016\/j.forsciint.2025.112763_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.08.013","article-title":"Identification and management of acute alcohol intoxication","volume":"108","author":"Mirijello","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.forsciint.2025.112763_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108019","article-title":"Treatment of overdose in the synthetic opioid era","volume":"233","author":"Skolnick","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.forsciint.2025.112763_bib25","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R4024","article-title":"Nitazenes are potent mu-opioid receptor agonists with profound respiratory depression","volume":"36","author":"Palkovic","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.forsciint.2025.112763_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107121","article-title":"Mu-opioid receptor selective superagonists produce prolonged respiratory depression","volume":"26","author":"Malcolm","year":"2023","journal-title":"iScience"}],"container-title":["Forensic Science International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073825004074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0379073825004074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:51:25Z","timestamp":1773870685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0379073825004074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S0379073825004074"],"URL":"https:\/\/doi.org\/10.1016\/j.forsciint.2025.112763","relation":{},"ISSN":["0379-0738"],"issn-type":[{"value":"0379-0738","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postmortem distribution of isotonitazene and its three metabolites in the first lethal case observed in France","name":"articletitle","label":"Article Title"},{"value":"Forensic Science International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.forsciint.2025.112763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112763"}}